AgeX Therapeutics (AgeX) a subsidiary of BioTime, Inc. (NYSE American: BTX) introduced a newly-published peer-reviewed research that reveals genes implicated in tissue regeneration, most cancers, and getting older. The research, by scientists at AgeX and BioTime, in collaboration with Insilico Medicine, utilized synthetic intelligence (AI) expertise to parse tens of millions of gene expression information factors to decipher the complicated mechanisms controlling pure tissue regeneration. The outcomes, revealed within the peer-reviewed scientific journal Oncotarget, confirmed that the candidate genes are expressed otherwise in tissues early in improvement when they’re able to regeneration in comparison with later in life when regeneration can now not take

This article sources info from